Published in J Interferon Cytokine Res on February 24, 2014
The Janus kinase inhibitor ruxolitinib reduces HIV replication in human macrophages and ameliorates HIV encephalitis in a murine model. Neurobiol Dis (2016) 0.79
Cerebrospinal fluid interferon alpha levels correlate with neurocognitive impairment in ambulatory HIV-Infected individuals. J Neurovirol (2016) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. Proc Natl Acad Sci U S A (2000) 3.77
Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell (1995) 3.51
Human immunodeficiency virus-associated neurocognitive disorders: Mind the gap. Ann Neurol (2010) 2.96
Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. Arch Neurol (2010) 2.91
Cytokine expression in the brain during the acquired immunodeficiency syndrome. Ann Neurol (1992) 2.52
Cytokines and arachidonic metabolites produced during human immunodeficiency virus (HIV)-infected macrophage-astroglia interactions: implications for the neuropathogenesis of HIV disease. J Exp Med (1992) 2.48
The vaccinia virus soluble alpha/beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN. J Virol (2000) 2.08
Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum (2013) 2.06
Beta-chemokines MCP-1 and RANTES are selectively increased in cerebrospinal fluid of patients with human immunodeficiency virus-associated dementia. Ann Neurol (1998) 2.05
Human immunodeficiency virus encephalitis is the pathological correlate of dementia in acquired immunodeficiency syndrome. Ann Neurol (1994) 1.52
Patterns of gene dysregulation in the frontal cortex of patients with HIV encephalitis. J Neuroimmunol (2004) 1.29
A model of human immunodeficiency virus encephalitis in scid mice. Proc Natl Acad Sci U S A (1993) 1.25
HIV, antiretroviral therapies, and the brain. Curr HIV/AIDS Rep (2010) 1.20
Active anti-interferon-alpha immunization: a European-Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1--infected patients (the EURIS study). J Acquir Immune Defic Syndr Hum Retrovirol (1999) 1.20
Improvement in HIV-associated motor slowing after antiretroviral therapy including protease inhibitors. J Neurovirol (2000) 1.20
Interferon-alpha causes neuronal dysfunction in encephalitis. J Neurosci (2009) 1.18
Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol (1998) 1.16
Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report. Neurology (2006) 1.16
Secreted immunomodulatory viral proteins as novel biotherapeutics. J Immunol (2004) 1.13
Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis. Lancet Neurol (2005) 1.10
Inhibition of type I and type III interferons by a secreted glycoprotein from Yaba-like disease virus. Proc Natl Acad Sci U S A (2007) 1.08
Targeting the glutamatergic system for the treatment of HIV-associated neurocognitive disorders. J Neuroimmune Pharmacol (2013) 1.08
A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann Rheum Dis (2013) 1.06
Cognitive dysfunction in HIV encephalitic SCID mice correlates with levels of Interferon-alpha in the brain. AIDS (2007) 1.06
A potential role for interferon-alpha in the pathogenesis of HIV-associated dementia. Brain Behav Immun (1995) 1.03
Analysis of an interaction between the soluble vaccinia virus-coded type I interferon (IFN)-receptor and human IFN-alpha1 and IFN-alpha2. Virology (1997) 1.01
SCID mice with HIV encephalitis develop behavioral abnormalities. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 1.00
Highly active antiretroviral therapy and human immunodeficiency virus encephalitis. Ann Neurol (2005) 0.98
Blood-brain barrier abnormalities caused by HIV-1 gp120: mechanistic and therapeutic implications. ScientificWorldJournal (2012) 0.97
Cytokine-binding proteins: stimulating antagonists. Immunol Today (1995) 0.96
Cognitive dysfunction and depression during treatment with interferon-alpha and chemotherapy. J Neuropsychiatry Clin Neurosci (2004) 0.95
A randomized clinical trial of CPI-1189 for HIV-associated cognitive-motor impairment. Neurology (2002) 0.92
Randomized trial of minocycline in the treatment of HIV-associated cognitive impairment. Neurology (2012) 0.91
Partial IFN-alpha/beta and IFN-gamma receptor knockout trisomy 16 mouse fetuses show improved growth and cultured neuron viability. J Interferon Cytokine Res (2000) 0.90
Interferon-α (IFNα) neurotoxicity. Cytokine Growth Factor Rev (2012) 0.89
Highly active antiretroviral therapy of cognitive dysfunction and neuronal abnormalities in SCID mice with HIV encephalitis. Exp Neurol (2007) 0.89
Measuring HIV-1 RNA and interferon-alpha in the cerebrospinal fluid of AIDS patients: insights into the pathogenesis of AIDS Dementia Complex. J Neurovirol (1999) 0.88
Randomized trial of the platelet-activating factor antagonist lexipafant in HIV-associated cognitive impairment. Neurological AIDS Research Consortium. Neurology (1999) 0.85
Microglia in HIV-associated neurological diseases. Microsc Res Tech (2001) 0.84
Role of anti-interferon antibodies in breakthrough occurrence during alpha 2a and 2b therapy in patients with chronic hepatitis C. J Hepatol (1998) 0.84
Cerebrospinal and peripheral human immunodeficiency virus type 1 load in a multisite, randomized, double-blind, placebo-controlled trial of D-Ala1-peptide T-amide for HIV-1-associated cognitive-motor impairment. J Neurovirol (2006) 0.81
Enhancement of NMDA receptor-mediated excitatory postsynaptic currents by gp120-treated macrophages: implications for HIV-1-associated neuropathology. J Neuroimmune Pharmacol (2013) 0.80
Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proc Natl Acad Sci U S A (2010) 2.41
HIV-1 clade-specific differences in the induction of neuropathogenesis. J Neurosci (2008) 1.37
Interferon-alpha causes neuronal dysfunction in encephalitis. J Neurosci (2009) 1.18
Impact of opiate-HIV-1 interactions on neurotoxic signaling. J Neuroimmune Pharmacol (2006) 1.11
Clade C HIV-1 isolates circulating in Southern Africa exhibit a greater frequency of dicysteine motif-containing Tat variants than those in Southeast Asia and cause increased neurovirulence. Retrovirology (2013) 1.09
Upregulation of calpain correlates with increased neurodegeneration in acute experimental auto-immune encephalomyelitis. J Neurosci Res (2005) 1.08
Cognitive dysfunction in HIV encephalitic SCID mice correlates with levels of Interferon-alpha in the brain. AIDS (2007) 1.06
Increased calpain correlates with Th1 cytokine profile in PBMCs from MS patients. J Neuroimmunol (2007) 1.01
Highly active antiretroviral therapy and human immunodeficiency virus encephalitis. Ann Neurol (2005) 0.98
The severe combined immunodeficient (SCID) mouse model of human immunodeficiency virus encephalitis: deficits in cognitive function. J Neurovirol (2004) 0.91
Highly active antiretroviral therapy of cognitive dysfunction and neuronal abnormalities in SCID mice with HIV encephalitis. Exp Neurol (2007) 0.89
Interplay of drug metabolizing CYP450 enzymes and ABC transporters in the blood-brain barrier. Curr Drug Metab (2011) 0.89
Regulation of Th1/Th17 cytokines and IDO gene expression by inhibition of calpain in PBMCs from MS patients. J Neuroimmunol (2010) 0.88
Overexpression of human amyloidogenic light chains causes heart failure in embryonic zebrafish: a preliminary report. Amyloid (2012) 0.88
Association of acquired von Willebrand syndrome with AL amyloidosis. Am J Hematol (2007) 0.85
Combined antiretroviral therapy reduces brain viral load and pathological features of HIV encephalitis in a mouse model. J Neurovirol (2014) 0.79
Interferon-α induces neurotoxicity through activation of the type I receptor and the GluN2A subunit of the NMDA receptor. J Interferon Cytokine Res (2014) 0.78
Human ABC transporters at blood-CNS interfaces as determinants of CNS drug penetration. Curr Pharm Des (2014) 0.78
Neurosarcoidosis. Curr Treat Options Neurol (2007) 0.75
Generalized Yamaguchi correlation factor for coherent quadratic phase speckle metrology systems with an aperture. Opt Lett (2006) 0.75
Controlling speckle using lenses and free space. Opt Lett (2007) 0.75
PHARMACEUTICAL QUALITY OF GENERIC ATORVASTATIN PRODUCTS COMPARED WITH THE INNOVATOR PRODUCT: A NEED FOR REVISING PRICING POLICY IN PALESTINE. Acta Pol Pharm (2016) 0.75
Therapeutic options in neurosarcoidosis. Expert Rev Neurother (2002) 0.75
Paraxial speckle-based metrology systems with an aperture. J Opt Soc Am A Opt Image Sci Vis (2006) 0.75